Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
04 avr. 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 04, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas
29 mars 2023 03h01 HE
|
Mainz BioMed NV
Mainz Biomed’s proprietary nucleic acid extraction and PCR process proved to be highly effectiveTwo mRNA biomarkers found to be particularly valuable in detecting disease signals in advanced adenoma...
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
21 mars 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, March 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
15 mars 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection
08 mars 2023 03h01 HE
|
Mainz BioMed NV
Sponsor of Gastro Update 2023, 2-day scientific and training events for gastroenterology professionals Patient Education Day in the City of Mainz, Germany, where the Company is headquartered ...
Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023
01 mars 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, March 01, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed to Appear on ClearThink IR’s Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET
28 févr. 2023 08h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that...
Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
21 févr. 2023 03h01 HE
|
Mainz BioMed NV
Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY...
Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK
15 févr. 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
18 janv. 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, US and MAINZ, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early...